A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
Clinical trial NCT06612775 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06612775
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-01
- Primary completion
- 2026-08-01
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.